ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1435

Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis

Angelo Fassio1, GIovanni Adami 1, Ombretta Viapiana 1, Luca Idolazzi 1, Giovanni Orsolini 1, Alessandro Giollo 1, Davide Gatti 2 and Maurizio Rossini 1, 1University of Verona, Verona, Italy, 2Univerisity of Verona, Verona, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Bone, Rheumatoid arthritis (RA), tocilizumab and glucocorticoids, WNT Signaling

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Wnt signaling is an important regulator of bone remodeling and it is involved in the pathogenesis of focal and systemic bone loss in Rheumatoid Arthritis (RA) patients. The aim of the present study is to investigate the short-term effects of three different anti-inflammatory therapies on Wnt inhibitors and bone turnover markers (BTMs) in patients with early RA.

Methods: We performed a retrospective analysis of prospectively collected data. We enrolled women affected by early RA (< 12 months) according to 2010 ACR/EULAR criteria who started treatment with certolizumab pegol (200 mg SC weekly), tocilizumab (162 mg SC weekly) or methyl-predinsolone (8 mg daily). Women enrolled in the study were required to have positive RF and/or positive ACPA and active disease (DAS28 ≥2.6) despite stable treatment with subcutaneous methotrexate (10-15 mg/week) for at least 6 months. Clinical parameters and blood samples were collected at baseline, week 1 and week 4.

Results: Data were obtained for 14 patients treated with certolizumab pegol, 14 patients treated with tocilizumab and 20 patients treated with methyl-prednisolone. Mean DAS28 at baseline was 4.0 ± 0.7 No difference in any of the tested parameters was found at baseline. The percent changes of the serum levels of bone turnover markers, Dkk-1 and sclerostin are reported in Figure 1. CTX-I, Dkk-1 and sclerostin decreased abruptly after 1 week of treatment with certolizumab pegol (-27% ± 21.5%, -50% ± 13.2% and -30% ± 30.4% respectively), and similar results were found after 4 weeks. Methyl-prednisolone induced comparable changes, albeit less evident, on CTX-I and Wnt inhibitors. We found an increase in PINP serum levels after treatment with anti-TNFα, while we observed a decrease with methyl-prednisolone. Tocilizumab did not significantly affect BTMs or Wnt inhibitors.

Conclusion: TNFα inhibition seems to have a strong and quick effect on BTMs and Wnt inhibitors, which was not observed with IL-6 blockade, at least in the short-term. Glucocorticoid treatment exerts similar, though less prominent, changes, potentially linked to the suppression of inflammation, nonetheless it still show some undesired effects on bone metabolism (ie, suppression of bone formation).

Figure 1. Bone turnover markers and Wnt inhibitors changes after 1 and 4 weeks of treatment with methyl-prednisolone -MPONE-, tocilizumab -TCZ- and certolizumab pegol -CMZ-


Disclosure: A. Fassio, None; G. Adami, None; O. Viapiana, Abiogen; L. Idolazzi, None; G. Orsolini, None; A. Giollo, None; D. Gatti, None; M. Rossini, Abiogen, 5, Biogen, 5, Eli Lilly, 5, 8, Novartis, 5, UCB, 5.

To cite this abstract in AMA style:

Fassio A, Adami G, Viapiana O, Idolazzi L, Orsolini G, Giollo A, Gatti D, Rossini M. Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/acute-effects-of-il-6-blockade-tnf%ce%b1-inhibitor-or-glucocorticoids-on-bone-turnover-markers-and-wnt-inhibitors-in-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acute-effects-of-il-6-blockade-tnf%ce%b1-inhibitor-or-glucocorticoids-on-bone-turnover-markers-and-wnt-inhibitors-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology